Journal of Nuclear Medicine最新文献

{"title":"Second Symposium of the European Working Group on the Radiobiology of Molecular Radionuclide Therapy.","authors":"Julie Nonnekens, Bart Cornelissen, Samantha Y A Terry","doi":"10.2967/jnumed.123.265956","DOIUrl":"10.2967/jnumed.123.265956","url":null,"abstract":"<p><p>Molecular radionuclide therapy is a relatively novel anticancer treatment option using radiolabeled, tumor-specific vectors. On binding of these vectors to cancer cells, radioactive decay induces DNA damage and other effects, leading to cancer cell death. Treatments, such as with [¹⁷⁷Lu]Lu-octreotate for neuroendocrine tumors and [¹⁷⁷Lu]Lu-PSMA for prostate cancer, are now being implemented into routine clinical practice around the world. Nonetheless, research into the underlying radiobiologic effects of these treatments is essential to further improve them or formulate new ones. The purpose of the European Working Group on the Radiobiology of Molecular Radiotherapy is to promote knowledge, investment, and networking in this area. This report summarizes recent research and insights presented at the second International Workshop on Radiobiology of Molecular Radiotherapy, held in London, U.K., on March 13 and 14, 2023. The symposium was organized by members of the Cancer Research U.K. RadNet City of London and the European Working Group on the Radiobiology of Molecular Radiotherapy.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1788-1790"},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9775954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-Low Breast Cancer Can Be Visualized by HER2 PET.","authors":"Renske Altena,&nbsp;Siri Af Burén,&nbsp;Thuy Tran,&nbsp;Rimma Axelsson","doi":"10.2967/jnumed.123.266101","DOIUrl":"10.2967/jnumed.123.266101","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1841"},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10246110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [⁶⁸Ga]Ga-FAPI-46 PET-Positive and [¹⁸F]FDG PET-Negative.","authors":"Peter George Maliha,&nbsp;Abie H Mendelsohn,&nbsp;Johannes Czernin,&nbsp;Taylor Howard,&nbsp;Jeremie Calais,&nbsp;Masatoshi Hotta","doi":"10.2967/jnumed.123.265498","DOIUrl":"10.2967/jnumed.123.265498","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1839-1840"},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9522832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total-Body Perfusion Imaging with [¹¹C]-Butanol.","authors":"Elizabeth J Li, Javier E López, Benjamin A Spencer, Yasser Abdelhafez, Ramsey D Badawi, Guobao Wang, Simon R Cherry","doi":"10.2967/jnumed.123.265659","DOIUrl":"10.2967/jnumed.123.265659","url":null,"abstract":"<p><p>Tissue perfusion can be affected by physiology or disease. With the advent of total-body PET, quantitative measurement of perfusion across the entire body is possible. [¹¹C]-butanol is a perfusion tracer with a superior extraction fraction compared with [¹⁵O]-water and [¹³N]-ammonia. To develop the methodology for total-body perfusion imaging, a pilot study using [¹¹C]-butanol on the uEXPLORER total-body PET/CT scanner was conducted. <b>Methods:</b> Eight participants (6 healthy volunteers and 2 patients with peripheral vascular disease [PVD]) were injected with a bolus of [¹¹C]-butanol and underwent 30-min dynamic acquisitions. Three healthy volunteers underwent repeat studies at rest (baseline) to assess test-retest reproducibility; 1 volunteer underwent paired rest and cold pressor test (CPT) studies. Changes in perfusion were measured in the paired rest-CPT study. For PVD patients, local changes in perfusion were investigated and correlated with patient medical history. Regional and parametric kinetic analysis methods were developed using a 1-tissue compartment model and leading-edge delay correction. <b>Results:</b> Estimated baseline perfusion values ranged from 0.02 to 1.95 mL·min^-1·cm^-3 across organs. Test-retest analysis showed that repeat baseline perfusion measurements were highly correlated (slope, 0.99; Pearson <i>r</i> = 0.96, <i>P</i> < 0.001). For the CPT subject, the largest regional increases were in skeletal muscle (psoas, 142%) and the myocardium (64%). One of the PVD patients showed increased collateral vessel growth in the calf because of a peripheral stenosis. Comorbidities including myocardial infarction, hypothyroidism, and renal failure were correlated with variations in organ-specific perfusion. <b>Conclusion:</b> This pilot study demonstrates the ability to obtain reproducible measurements of total-body perfusion using [¹¹C]-butanol. The methods are sensitive to local perturbations in flow because of physiologic stressors and disease.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1831-1838"},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease.","authors":"Farzaneh Rezazadeh, Nicholas Ramos, Allen-Dexter Saliganan, Najeeb Al-Hallak, Kang Chen, Bashar Mohamad, Wendy N Wiesend, Nerissa T Viola","doi":"10.2967/jnumed.123.265649","DOIUrl":"10.2967/jnumed.123.265649","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD), which includes both Crohn disease and ulcerative colitis, is a relapsing inflammatory disease of the gastrointestinal tract. Long-term chronic inflammatory conditions elevate the patient's risk of colorectal cancer (CRC). Currently, diagnosis requires endoscopy with biopsy. This procedure is invasive and requires a bowel-preparatory regimen, adding to patient burden. Interleukin 12 (IL12) and interleukin 23 (IL23) play key roles in inflammation, especially in the pathogenesis of IBD, and are established therapeutic targets. We propose that imaging of IL12/23 and its p40 subunit in IBD via immuno-PET potentially provides a new noninvasive diagnostic approach. <b>Methods:</b> Our aim was to investigate the potential of immuno-PET to image inflammation in a chemically induced mouse model of colitis using dextran sodium sulfate by targeting IL12/23p40 with a ⁸⁹Zr-radiolabeled anti-IL12/23p40 antibody. <b>Results:</b> High uptake of the IL12/23p40 immuno-PET agent was exhibited by dextran sodium sulfate-administered mice, and this uptake correlated with increased IL12/23p40 present in the sera. Competitive binding studies confirmed the specificity of the radiotracer for IL12/23p40 in the gastrointestinal tract. <b>Conclusion:</b> These promising results demonstrate the utility of this radiotracer as an imaging biomarker of IBD. Moreover, IL12/23p40 immuno-PET can potentially guide treatment decisions for IBD management.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1806-1814"},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10203981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total-Body Multiparametric PET Quantification of ¹⁸F-FDG Delivery and Metabolism in the Study of Coronavirus Disease 2019 Recovery.","authors":"Yiran Wang, Lorenzo Nardo, Benjamin A Spencer, Yasser G Abdelhafez, Elizabeth J Li, Negar Omidvari, Abhijit J Chaudhari, Ramsey D Badawi, Terry Jones, Simon R Cherry, Guobao Wang","doi":"10.2967/jnumed.123.265723","DOIUrl":"10.2967/jnumed.123.265723","url":null,"abstract":"<p><p>Conventional whole-body static ¹⁸F-FDG PET imaging provides a semiquantitative evaluation of overall glucose metabolism without insight into the specific transport and metabolic steps. Here we demonstrate the ability of total-body multiparametric ¹⁸F-FDG PET to quantitatively evaluate glucose metabolism using macroparametric quantification and assess specific glucose delivery and phosphorylation processes using microparametric quantification for studying recovery from coronavirus disease 2019 (COVID-19). <b>Methods:</b> The study included 13 healthy subjects and 12 recovering COVID-19 subjects within 8 wk of confirmed diagnosis. Each subject had a 1-h dynamic ¹⁸F-FDG scan on the uEXPLORER total-body PET/CT system. Semiquantitative SUV and the SUV ratio relative to blood (SUVR) were calculated for different organs to measure glucose utilization. Tracer kinetic modeling was performed to quantify the microparametric blood-to-tissue ¹⁸F-FDG delivery rate [Formula: see text] and the phosphorylation rate <i>k</i> ₃, as well as the macroparametric ¹⁸F-FDG net influx rate ([Formula: see text]). Statistical tests were performed to examine differences between healthy subjects and recovering COVID-19 subjects. The effect of COVID-19 vaccination was also investigated. <b>Results:</b> We detected no significant difference in lung SUV but significantly higher lung SUVR and [Formula: see text] in COVID-19 recovery, indicating improved sensitivity of kinetic quantification for detecting the difference in glucose metabolism. A significant difference was also observed in the lungs with the phosphorylation rate <i>k</i> ₃ but not with [Formula: see text], which suggests that glucose phosphorylation, rather than glucose delivery, drives the observed difference of glucose metabolism. Meanwhile, there was no or little difference in bone marrow ¹⁸F-FDG metabolism measured with SUV, SUVR, and [Formula: see text] but a significantly higher bone marrow [Formula: see text] in the COVID-19 group, suggesting a difference in glucose delivery. Vaccinated COVID-19 subjects had a lower lung [Formula: see text] and a higher spleen [Formula: see text] than unvaccinated COVID-19 subjects. <b>Conclusion:</b> Higher lung glucose metabolism and bone marrow glucose delivery were observed with total-body multiparametric ¹⁸F-FDG PET in recovering COVID-19 subjects than in healthy subjects, implying continued inflammation during recovery. Vaccination demonstrated potential protection effects. Total-body multiparametric PET of ¹⁸F-FDG can provide a more sensitive tool and more insights than conventional whole-body static ¹⁸F-FDG imaging to evaluate metabolic changes in systemic diseases such as COVID-19.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1821-1830"},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10498200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study.","authors":"Jingliang Zhang,&nbsp;Fei Kang,&nbsp;Jie Gao,&nbsp;Jianhua Jiao,&nbsp;Zhiyong Quan,&nbsp;Shuaijun Ma,&nbsp;Yu Li,&nbsp;Shikuan Guo,&nbsp;Zeyu Li,&nbsp;Yuming Jing,&nbsp;Keying Zhang,&nbsp;Fa Yang,&nbsp;Donghui Han,&nbsp;Weihong Wen,&nbsp;Jing Zhang,&nbsp;Jing Ren,&nbsp;Jing Wang,&nbsp;Hongqian Guo,&nbsp;Weijun Qin","doi":"10.2967/jnumed.122.265001","DOIUrl":"10.2967/jnumed.122.265001","url":null,"abstract":"<p><p>The preoperative Gleason grade group (GG) from transrectal ultrasound-guided prostate biopsy is crucial for treatment decisions but may underestimate the postoperative GG and miss clinically significant prostate cancer (csPCa), particularly in patients with biopsy GG1. In such patients, an SUV_max of at least 12 has 100% specificity for detecting csPCa. In patients with an SUV_max of less than 12, we aimed to develop a model to improve the diagnostic accuracy of csPCa. <b>Methods:</b> The study retrospectively included 56 prostate cancer patients with transrectal ultrasound-guided biopsy GG1 and an SUV_max of less than 12 from 2 tertiary hospitals. All [⁶⁸Ga]Ga-PSMA-HBED-CC PET scans were centrally reviewed in Xijing Hospital. A deep learning model was used to evaluate the overlap of SUV_max (size scale, 3 cm) and the level of Gleason pattern (size scale, 500 μm). A diagnostic model was developed using the PRIMARY score and SUV_max, and its discriminative performance and clinical utility were compared with other methods. The 5-fold cross-validation (repeated 1,000 times) was used for internal validation. <b>Results:</b> In patients with GG1 and an SUV_max of less than 12, significant prostate-specific membrane antigen (PSMA) histochemical score (H-score) H-score overlap occurred among benign gland, Gleason pattern 3, and Gleason pattern 4 lesions, causing SUV_max overlap between csPCa and non-csPCa. The model of 10 × PRIMARY score + 2 × SUV_max exhibited a higher area under the curve (AUC, 0.8359; 95% CI, 0.7233-0.9484) than that found using only the SUV_max (AUC, 0.7353; <i>P</i> = 0.048) or PRIMARY score (AUC, 0.7257; <i>P</i> = 0.009) for the cohort and a higher AUC (0.8364; 95% CI, 0.7114-0.9614) than that found using only the Prostate Imaging Reporting and Data System (PI-RADS) score of 5-4 versus 3-1 (AUC, 0.7036; <i>P</i> = 0.149) and the PI-RADS score of 5-3 versus 2-1 (AUC, 0.6373; <i>P</i> = 0.014) for a subgroup. The model reduced the misdiagnosis of the PI-RADS score of 5-4 versus 3-1 by 78.57% (11/14) and the PI-RADS score of 5-3 versus 2-1 by 77.78% (14/18). The internal validation showed that the mean 5-fold cross-validated AUC was 0.8357 (95% CI, 0.8357-0.8358). <b>Conclusion:</b> We preliminarily suggest that the model of 10 × PRIMARY score + 2 × SUV_max may enhance the diagnostic accuracy of csPCa in patients with biopsy GG1 and an SUV_max of less than 12 by maximizing PSMA information use, reducing the misdiagnosis of the PI-RADS score, and thereby aiding in making appropriate treatment decisions.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1750-1757"},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for ⁸⁹Zr-Trastuzumab.","authors":"Philipp Mohr,&nbsp;Joyce van Sluis,&nbsp;Laura Providência,&nbsp;Johannes H van Snick,&nbsp;Marjolijn N Lub-de Hooge,&nbsp;Antoon T Willemsen,&nbsp;Andor W J M Glaudemans,&nbsp;Ronald Boellaard,&nbsp;Adriaan A Lammertsma,&nbsp;Adrienne H Brouwers,&nbsp;Charalampos Tsoumpas","doi":"10.2967/jnumed.123.265621","DOIUrl":"10.2967/jnumed.123.265621","url":null,"abstract":"<p><p>The purpose of this study was to quantify any differences between the SUVs of ⁸⁹Zr immuno-PET scans obtained using a PET/CT system with a long axial field of view (LAFOV; Biograph Vision Quadra) compared to a PET/CT system with a short axial field of view (SAFOV; Biograph Vision) and to evaluate how LAFOV PET scan duration affects image noise and SUV metrics. <b>Methods:</b> Five metastatic breast cancer patients were scanned consecutively on SAFOV and LAFOV PET/CT scanners. Four additional patients were scanned using only LAFOV PET/CT. Scans on both systems lasted approximately 30 min and were acquired 4 d after injection of 37 MBq of ⁸⁹Zr-trastuzumab. LAFOV list-mode data were reprocessed to obtain images acquired using shorter scan durations (15, 10, 7.5, 5, and 3 min). Volumes of interest were placed in healthy tissues, and tumors were segmented semiautomatically to compare coefficients of variation and to perform Bland-Altman analysis on SUV metrics (SUV_max, SUV_peak, and SUV_mean). <b>Results:</b> Using 30-min images, 2 commonly used lesion SUV metrics were higher for SAFOV than for LAFOV PET (SUV_max, 16.2% ± 13.4%, and SUV_peak, 10.1% ± 7.2%), whereas the SUV_mean of healthy tissues showed minimal differences (0.7% ± 5.8%). Coefficients of variation in the liver derived from 30-min SAFOV PET were between those of 3- and 5-min LAFOV PET. The smallest SUV_max and SUV_peak differences between SAFOV and LAFOV were found for 3-min LAFOV PET. <b>Conclusion:</b> LAFOV ⁸⁹Zr immuno-PET showed a lower SUV_max and SUV_peak than SAFOV because of lower image noise. LAFOV PET scan duration may be reduced at the expense of increasing image noise and bias in SUV metrics. Nevertheless, SUV_peak showed only minimal bias when reducing scan duration from 30 to 10 min.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1815-1820"},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9936955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Tumor Uptake on ¹⁸F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d'étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network.","authors":"Ophélie De Rycke,&nbsp;Marine Perrier,&nbsp;Éric Ouvrard,&nbsp;Clément Mennetrey,&nbsp;Choaib Lachachi,&nbsp;Aurélie Bando-Delaunay,&nbsp;David Morland,&nbsp;Bernard Goichot,&nbsp;David Taieb,&nbsp;Thomas Walter,&nbsp;Guillaume Cadiot,&nbsp;Jérôme Cros,&nbsp;Olivia Hentic,&nbsp;Philippe Ruszniewski,&nbsp;Rachida Lebtahi,&nbsp;Alessio Imperiale,&nbsp;Louis de Mestier","doi":"10.2967/jnumed.123.265584","DOIUrl":"10.2967/jnumed.123.265584","url":null,"abstract":"Visual Abstract PET/CT with 6-18F-fluoro-l-dopa (18F-FDOPA) has high diagnostic performance for midgut neuroendocrine tumors (NETs). We explored the prognostic role of 18F-FDOPA PET/CT uptake in metastatic midgut NETs. Methods: We included, in a test cohort (n = 166) and a full external validation cohort (n = 86), all consecutive patients with metastatic midgut NETs who underwent 18F-FDOPA PET/CT in 5 expert centers from 2010 to 2021. We measured the maximal uptake (SUVmax and SUVpeak) of the tumor and nontumor liver on each 18F-FDOPA PET/CT scan. We measured overall survival (OS) from the time of PET/CT and assessed prognostic factors using Kaplan–Meier and multivariable Cox proportional-hazards analyses in the test cohort, with replication in the validation cohort. Results: Patients had similar characteristics in both cohorts. In the test cohort, median follow-up was 60.3 mo. Patients with an SUVpeak tumor-to-liver (T/L) ratio of more than 4.2 had significantly shorter survival than those with a ratio of 4.2 or less (P = 0.01), with a 5-y OS rate of 74.1% ± 4.5% versus 95% ± 3.4%, respectively. On multivariable analysis, an SUVpeak T/L ratio of more than 4.2 remained associated with shorter OS (hazard ratio, 2.30; 95% CI, 1.02–5.22; P = 0.046) after adjustment for age, grade, number of previous lines, number of metastatic sites, and presence of carcinoid syndrome. In the validation cohort, the 5-y OS rate was 100% versus 57.8% ± 12.5% in patients with an SUVpeak T/L ratio ≤ 4.2 or > 4.2, respectively (P = 0.075). An increasing SUVpeak T/L ratio over time tended to have a pejorative prognostic impact. Conclusion: Tumor uptake on 18F-FDOPA PET/CT is an independent prognostic factor in patients with metastatic midgut NETs.","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1699-1705"},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.","authors":"Romain-David Seban","doi":"10.2967/jnumed.123.266490","DOIUrl":"10.2967/jnumed.123.266490","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1841-1842"},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10246117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}